Fox Run Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-16,166
| Closed | -$1.29M | – | 1039 |
|
|
2026
Q1 | $1.29M | Sell |
16,166
-8,142
| -33% | -$671K | 0.22% | 103 |
|
|
2025
Q4 | $2.07M | Buy |
+24,308
| New | +$1.99M | 0.32% | 27 |
|
|
2024
Q4 | – | Sell |
-6,498
| Closed | -$429K | – | 961 |
|
|
2024
Q3 | $429K | Buy |
+6,498
| New | +$472K | 0.1% | 417 |
|
|
2024
Q2 | – | Sell |
-12,926
| Closed | -$1.24M | – | 860 |
|
|
2024
Q1 | $1.24M | Buy |
+12,926
| New | +$1.09M | 0.27% | 75 |
|
|
2023
Q4 | – | Sell |
-9,990
| Closed | -$692K | – | 809 |
|
|
2023
Q3 | $692K | Buy |
+9,990
| New | +$803K | 0.2% | 162 |
|
|
2023
Q2 | – | Sell |
-5,680
| Closed | -$470K | – | 766 |
|
|
2023
Q1 | $470K | Sell |
5,680
-2,077
| -27% | -$163K | 0.15% | 239 |
|
|
2022
Q4 | $579K | Buy |
7,757
+1,355
| +21% | +$104K | 0.23% | 126 |
|
|
2022
Q3 | $529K | Buy |
+6,402
| New | +$616K | 0.21% | 159 |
|
|
2022
Q2 | – | Sell |
-2,586
| Closed | -$304K | – | 594 |
|
|
2022
Q1 | $304K | Buy |
+2,586
| New | +$290K | 0.17% | 270 |
|
|
2021
Q3 | – | Sell |
-3,108
| Closed | -$322K | – | 513 |
|
|
2021
Q2 | $322K | Buy |
+3,108
| New | +$293K | 0.29% | 146 |
|
|
2020
Q1 | – | Sell |
-4,875
| Closed | -$379K | – | 193 |
|
|
2019
Q4 | $379K | Buy |
+4,875
| New | +$381K | 0.31% | 108 |
|
|
2019
Q1 | – | Sell |
-14,031
| Closed | -$716K | – | 532 |
|
|
2018
Q4 | $716K | Buy |
14,031
+8,859
| +171% | +$448K | 0.38% | 34 |
|
|
2018
Q3 | $300K | Sell |
5,172
-6,945
| -57% | -$340K | 0.13% | 345 |
|
|
2018
Q2 | $588K | Buy |
+12,117
| New | +$566K | 0.19% | 175 |
|
|
2017
Q4 | – | Sell |
-40,200
| Closed | -$1.47M | – | 733 |
|
|
2017
Q3 | $1.47M | Buy |
40,200
+27,900
| +227% | +$1.06M | 0.41% | 10 |
|
|
2017
Q2 | $485K | Sell |
12,300
-31,800
| -72% | -$1.16M | 0.17% | 229 |
|
|
2017
Q1 | $1.38M | Buy |
+44,100
| New | +$1.38M | 0.56% | 2 |
|
|
2016
Q3 | – | Sell |
-19,800
| Closed | -$658K | – | 547 |
|
|
2016
Q2 | $658K | Sell |
19,800
-1,200
| -6% | -$41.1K | 0.32% | 59 |
|
|
2016
Q1 | $617K | Sell |
21,000
-8,400
| -29% | -$232K | 0.41% | 42 |
|
|
2015
Q4 | $774K | Buy |
+29,400
| New | +$763K | 0.6% | 10 |
|
Other funds holding EW
Fox Run Management's EW Position: Q2 2026 in Review
Fox Run Management sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 16,166 shares — an estimated $1.29M sold.
Fox Run Management first reported a position in EW in Q4 2015 and held it in 20 quarters. The position peaked at $2.07M in Q4 2025. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Fox Run Management reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
- Fox Run Management sold 16,166 Edwards Lifesciences shares in Q2 2026, an estimated $1.29M.
- Fox Run Management first reported a position in Edwards Lifesciences in Q4 2015 and held it in 20 quarters.
- Fox Run Management's Edwards Lifesciences position peaked at $2.07M in Q4 2025.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.